AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22911697 — intervention group
Group type: EXPERIMENTAL
Intervention: HBV co-infection
Number of subjects: 3441
Study 22911697 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV-RNA >800,000 IU/ml
Number of subjects: 3441
Study 22911697 — intervention group
Group type: COMPARATOR
Intervention: HCV-RNA undetectable or low
Number of subjects: 3441
Study 22911697 — intervention group
Group type: EXPERIMENTAL
Intervention: Interleukin-6, hyaluronic acid, FIB-4 hepatic fibrosis index
Number of subjects: 3441
Study 22911730 — intervention group
Group type: EXPERIMENTAL
Intervention: Bezafibrate (BF) at a dose of 400 mg daily for 12 weeks, followed by 800 mg daily for another 12 weeks.
Number of subjects: 10
Study 22912618 — intervention group
Group type: EXPERIMENTAL
Intervention: tDCS (anodal stimulation to the left DLPFC and cathodal stimulation to the right DLPFC)
Number of subjects: 24
Study 22912618 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 24
Study 22913682 — intervention group
Group type: EXPERIMENTAL
Intervention: High-titer anti-interferon-γ autoantibodies
Number of subjects: 203
Study 22913682 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutralizing anti-interferon-γ autoantibodies
Number of subjects: 203
Study 22913891 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide 10-μg BID
Number of subjects: 2067
Study 22913906 — intervention group
Group type: EXPERIMENTAL
Intervention: LAP-BAND AP® System (LBAP)
Number of subjects: 517
Study 22913907 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporine (100-mg capsule)
Number of subjects: 24
Study 22915450 — intervention group
Group type: EXPERIMENTAL
Intervention: Vorinostat (SAHA); individualized dose escalation; specific dosage and duration not provided.
Number of subjects: 0
Study 22915641 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide (10 mg/d for 21 days; 28-day cycle) and Azacitidine (75 mg/m(2)/d for 5 days)
Number of subjects: 36
Study 22915641 — intervention group
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Azacitidine combination
Number of subjects: 36
Study 22915649 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozrolimupab (75 to 300 μg/kg)
Number of subjects: 61
Study 22915649 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozrolimupab (300 μg/kg)
Number of subjects: 61
Study 22915649 — intervention group
Group type: EXPERIMENTAL
Intervention: Rozrolimupab
Number of subjects: 61
Study 22915656 — intervention group
Group type: EXPERIMENTAL
Intervention: FOLFOX4 (oxaliplatin with fluoropyrimidine)
Number of subjects: 2246
Study 22916254 — intervention group
Group type: EXPERIMENTAL
Intervention: Minor allele homozygotes for rs7903146 in healthy young males
Number of subjects: 218
Study 22916254 — intervention group
Group type: EXPERIMENTAL
Intervention: Carriers of the minor allele for rs7903146 in healthy elderly persons
Number of subjects: 218
Study 22916254 — intervention group
Group type: COMPARATOR
Intervention: rs7903146 in MetS patients
Number of subjects: 218
Study 22917457 — intervention group
Group type: EXPERIMENTAL
Intervention: Formalized data feedback
Number of subjects: 1183
Study 22917945 — intervention group
Group type: COMPARATOR
Intervention: Control group participation
Number of subjects: 60
Study 22920044 — intervention group
Group type: EXPERIMENTAL
Intervention: Group Psychodynamic Interpersonal Psychotherapy (GPIP) for high attachment anxiety participants
Number of subjects: 102
Study 22920044 — intervention group
Group type: COMPARATOR
Intervention: Group Psychodynamic Interpersonal Psychotherapy (GPIP) for low attachment anxiety participants
Number of subjects: 102
Study 22920644 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib with dexamethasone
Number of subjects: 0
Study 22920644 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of novel agents with high cut-off hemodialysis membrane
Number of subjects: 0
Study 22920644 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for MCN (urgent symptomatic measures and chemotherapy)
Number of subjects: 0
Study 22920685 — intervention group
Group type: EXPERIMENTAL
Intervention: (166)Ho-radioembolisation at 20 Gy (n=6)
Number of subjects: 15
Study 22920685 — intervention group
Group type: EXPERIMENTAL
Intervention: (166)Ho-radioembolisation at 40 Gy (n=3)
Number of subjects: 15
Study 22920685 — intervention group
Group type: EXPERIMENTAL
Intervention: (166)Ho-radioembolisation at 60 Gy (n=3)
Number of subjects: 15
Study 22920685 — intervention group
Group type: EXPERIMENTAL
Intervention: (166)Ho-radioembolisation at 80 Gy (n=3)
Number of subjects: 15
Study 22920685 — intervention group
Group type: EXPERIMENTAL
Intervention: (166)Ho-radioembolisation
Number of subjects: 15
Study 22921474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 30mg
Number of subjects: 13
Study 22921474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 60mg
Number of subjects: 13
Study 22921474 — intervention group
Group type: EXPERIMENTAL
Intervention: Dronabinol 120mg
Number of subjects: 13
Study 22921474 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 22922469 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS 2 group (n=12)
Number of subjects: 25
Study 22922469 — intervention group
Group type: EXPERIMENTAL
Intervention: CMS 1 group (n=13)
Number of subjects: 25
Study 22922469 — intervention group
Group type: COMPARATOR
Intervention: Lowlanders (control group)
Number of subjects: 25
Study 22922531 — intervention group
Group type: EXPERIMENTAL
Intervention: Aflibercept 4 mg/kg IV q14 days (28-day cycles) until disease progression or prohibitive toxicity
Number of subjects: 49
Study 22922703 — intervention group
Group type: EXPERIMENTAL
Intervention: Frontal Behavioral Inventory (FBI)
Number of subjects: 41
Study 22922703 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric Inventory (NPI)
Number of subjects: 41
Study 22922703 — intervention group
Group type: EXPERIMENTAL
Intervention: Zarit Burden Inventory (ZBI)
Number of subjects: 41
Study 22922703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-Mental State Examination (MMSE)
Number of subjects: 41
Study 22922703 — intervention group
Group type: EXPERIMENTAL
Intervention: Mattis Dementia Rating Scale (MDRS)
Number of subjects: 41
Study 22923433 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (mTOR inhibitor)
Number of subjects: 110
Study 22923433 — intervention group
Group type: COMPARATOR
Intervention: TSC1 mutation
Number of subjects: 110
Study 22923666 — intervention group
Group type: EXPERIMENTAL
Intervention: Bihormonal bionic endocrine pancreas
Number of subjects: 6
Study 22924125 — intervention group
Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 442
Study 22924433 — intervention group
Group type: EXPERIMENTAL
Intervention: Idarubicin-induced apoptosis >3 KU
Number of subjects: 109
Study 22924536 — intervention group
Group type: EXPERIMENTAL
Intervention: ATP1A3 gene mutations (R756H and D923N) in children
Number of subjects: 2
Study 22925036 — intervention group
Group type: EXPERIMENTAL
Intervention: Fondaparinux 1.5 mg qd for 6 to 15 days
Number of subjects: 206
Study 22925178 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin-grafted membrane with ordinary heparin dose
Number of subjects: 45
Study 22925178 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-molecular-weight heparin
Number of subjects: 45
Study 22925178 — intervention group
Group type: EXPERIMENTAL
Intervention: Unfractionated heparin
Number of subjects: 45
Study 22925750 — intervention group
Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 148
Study 22927100 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring balloon for side branch and drug-eluting stent for main vessel
Number of subjects: 93
Study 22927248 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesenchymal stem cell (MSC) treatment
Number of subjects: 0
Study 22927452 — intervention group
Group type: EXPERIMENTAL
Intervention: GII.4 norovirus challenge (5 x 10^4 RT-PCR units)
Number of subjects: 40
Study 22927751 — intervention group
Group type: EXPERIMENTAL
Intervention: InterVapor treatment
Number of subjects: 44
Study 22928607 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected subjects with ruptured intracranial aneurysm
Number of subjects: 2794
Study 22928607 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected subjects
Number of subjects: 2794
Study 22928607 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected subjects ≤60 years of age
Number of subjects: 2794
Study 22928607 — intervention group
Group type: EXPERIMENTAL
Intervention: Affected subjects ≥60 years of age
Number of subjects: 2794
Study 22928669 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic score based on clinical history data (e.g. hypertension, myocardial infarction, atrial fibrillation)
Number of subjects: 0
Study 22928669 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced score including additional factors such as blood-based biomarkers and results of vascular imaging
Number of subjects: 0
Study 22928669 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced score clinical utility assessment
Number of subjects: 0
Study 22928669 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vascular end-point
Number of subjects: 0
Study 22928669 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual components of the composite end-point
Number of subjects: 0
Study 22928669 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterns and time points of risk transitions
Number of subjects: 0
Study 22929184 — intervention group
Group type: EXPERIMENTAL
Intervention: Idursulfase weekly group
Number of subjects: 312
Study 22929184 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 312
Study 22929184 — intervention group
Group type: EXPERIMENTAL
Intervention: Idursulfase treatment group (extension phase)
Number of subjects: 312
Study 22929184 — intervention group
Group type: COMPARATOR
Intervention: Placebo group (extension phase)
Number of subjects: 312
Study 22929546 — intervention group
Group type: EXPERIMENTAL
Intervention: Facial burns
Number of subjects: 0
Study 22929546 — intervention group
Group type: COMPARATOR
Intervention: No facial burns
Number of subjects: 0
Study 22929546 — intervention group
Group type: EXPERIMENTAL
Intervention: Teenagers
Number of subjects: 0
Study 22929546 — intervention group
Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 0
Study 22929546 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents with higher education
Number of subjects: 0
Study 22929544 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-Center Benchmarking Study of four burn centers
Number of subjects: 1140
Study 22929547 — intervention group
Group type: EXPERIMENTAL
Intervention: Hand burns
Number of subjects: 438
Study 22929545 — intervention group
Group type: EXPERIMENTAL
Intervention: Burn Outcomes Questionnaire (BOQ)
Number of subjects: 1140
Study 22929545 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Form Psychosocial Questionnaire
Number of subjects: 1140
Study 22929549 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescent self-assessment using the BOQ
Number of subjects: 355
Study 22929551 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospitalization costs
Number of subjects: 230
Study 22929550 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-Form Psychosocial Questionnaire (SFPQ)
Number of subjects: 830
Study 22929550 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-Form Psychosocial Questionnaire (LFPQ)
Number of subjects: 830
Study 22930806 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (oral) for 14 days
Number of subjects: 48
Study 22931751 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial Period
Number of subjects: 0
Study 22931751 — intervention group
Group type: EXPERIMENTAL
Intervention: Eligible patients
Number of subjects: 0
Study 22931751 — intervention group
Group type: EXPERIMENTAL
Intervention: Final Period
Number of subjects: 0
Study 22932225 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma-specific T(CM) clones after in vitro expansion and differentiation
Number of subjects: 5
Study 22932225 — intervention group
Group type: EXPERIMENTAL
Intervention: Melanoma-specific T(CM) with high relative IL-2 production
Number of subjects: 5
Study 22932256 — intervention group
Group type: EXPERIMENTAL
Intervention: Menopausal hormone therapy (MHT)
Number of subjects: 1163
Study 22932256 — intervention group
Group type: COMPARATOR
Intervention: Low-density lipoprotein cholesterol (LDLC)
Number of subjects: 1163
Study 22932256 — intervention group
Group type: EXPERIMENTAL
Intervention: 27-hydroxycholesterol (27OHC)
Number of subjects: 1163
Study 22932804 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant monomeric sCD40L
Number of subjects: 0
Study 22932804 — intervention group
Group type: EXPERIMENTAL
Intervention: PBMCs cultured with sCD40L
Number of subjects: 0
Study 22932804 — intervention group
Group type: EXPERIMENTAL
Intervention: sCD40L
Number of subjects: 0
Study 22932804 — intervention group
Group type: EXPERIMENTAL
Intervention: Preexisting sCD40L
Number of subjects: 0
Study 22932804 — intervention group
Group type: EXPERIMENTAL
Intervention: MDSCs from cancer patients
Number of subjects: 0
Study 22932804 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cells cocultured with MDSCs
Number of subjects: 0
Study 22933539 — intervention group
Group type: EXPERIMENTAL
Intervention: FFA suppression
Number of subjects: 200
Study 22933539 — intervention group
Group type: EXPERIMENTAL
Intervention: IVGTT nadir palmitate concentration, VAT, UBSQ fat, fitness, and age
Number of subjects: 200
Study 22933539 — intervention group
Group type: EXPERIMENTAL
Intervention: meal nadir palmitate concentration, UBSQ fat, fitness, and sex
Number of subjects: 200
Study 22933606 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic periodontal inflammation model; periostin levels measured at baseline, 2 weeks, and 4 weeks.
Number of subjects: 0
Study 22933606 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic periodontal inflammation model; alveolar bone loss measured at baseline, 2 weeks, and 4 weeks.
Number of subjects: 0
Study 22933606 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation between periostin levels and alveolar bone loss.
Number of subjects: 0
Study 22933843 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Treatment
Number of subjects: 0
Study 22935168 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (OLAI)
Number of subjects: 1182
Study 22935398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazekas score 2
Number of subjects: 101
Study 22935398 — intervention group
Group type: EXPERIMENTAL
Intervention: Fazekas score 3
Number of subjects: 101
Study 22935398 — intervention group
Group type: EXPERIMENTAL
Intervention: Wahlund scores >10
Number of subjects: 101
Study 22935486 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginesatide administered intravenously every 4 weeks for up to 6 doses.
Number of subjects: 164
Study 22935486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohorts using tiered dose conversion tables.
Number of subjects: 164
Study 22935486 — intervention group
Group type: EXPERIMENTAL
Intervention: Cohorts using an erythropoiesis-stimulating agent-free interval.
Number of subjects: 164
Study 22935486 — intervention group
Group type: EXPERIMENTAL
Intervention: Safety profile of peginesatide.
Number of subjects: 164
Study 22935621 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-μg sublingual misoprostol
Number of subjects: 100
Study 22935620 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-μg sublingual misoprostol as first-line treatment
Number of subjects: 90
Study 22936711 — intervention group
Group type: EXPERIMENTAL
Intervention: Riociguat (1.0-2.5 mg three times daily for 12 weeks)
Number of subjects: 22
Study 22936827 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone marrow plasma from CHF patients
Number of subjects: 153
Study 22936827 — intervention group
Group type: EXPERIMENTAL
Intervention: BM plasma stimulation of human mesenchymal cells from CHF patients
Number of subjects: 153
Study 22936827 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate regression analysis
Number of subjects: 153
Study 22936827 — intervention group
Group type: EXPERIMENTAL
Intervention: Correlation analysis
Number of subjects: 153
Study 22938148 — intervention group
Group type: EXPERIMENTAL
Intervention: Portable electrocardiogram (ECG) recording during the marathon
Number of subjects: 110
Study 22938148 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 Tesla brain magnetic resonance imaging (MRI)
Number of subjects: 110
Study 22938148 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical examination (CE), carotid ultrasound imaging (CUI), serial blood sampling (BS)
Number of subjects: 110
Study 22938715 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery enlargement (PA:A ratio > 1)
Number of subjects: 0
Study 22939385 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 22939402 — intervention group
Group type: EXPERIMENTAL
Intervention: Nexplanon (etonogestrel implant)
Number of subjects: 301
Study 22939560 — intervention group
Group type: EXPERIMENTAL
Intervention: Bariatric surgery (BS)
Number of subjects: 23
Study 22939663 — intervention group
Group type: EXPERIMENTAL
Intervention: Two doses of seven-valent pneumococcal conjugate vaccine (PCV) given at a 4-week interval
Number of subjects: 429
Study 22939663 — intervention group
Group type: COMPARATOR
Intervention: One dose of seven-valent pneumococcal conjugate vaccine (PCV)
Number of subjects: 429
Study 22939663 — intervention group
Group type: EXPERIMENTAL
Intervention: Seven-valent PCV vaccination
Number of subjects: 429
Study 22939663 — intervention group
Group type: COMPARATOR
Intervention: HAART
Number of subjects: 429
Study 22939945 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-release quetiapine
Number of subjects: 25
Study 22940027 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/kg artesunate at 0, 24, and 48 h, 15 mg/kg mefloquine at 72 h, and 10 mg/kg mefloquine at 96 h
Number of subjects: 168
Study 22940371 — intervention group
Group type: COMPARATOR
Intervention: Grapefruit juice (240 mL twice daily for 4 days)
Number of subjects: 44
Study 22940371 — intervention group
Group type: COMPARATOR
Intervention: Seville orange juice (240 mL twice daily for 4 days)
Number of subjects: 44
Study 22940371 — intervention group
Group type: COMPARATOR
Intervention: Colchicine with grapefruit juice
Number of subjects: 44
Study 22940371 — intervention group
Group type: COMPARATOR
Intervention: Colchicine with Seville orange juice
Number of subjects: 44
Study 22940493 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV infection (any type)
Number of subjects: 16782
Study 22940493 — intervention group
Group type: EXPERIMENTAL
Intervention: Cytological abnormalities
Number of subjects: 16782
Study 22940493 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral risk factors (multivariable analysis)
Number of subjects: 16782
Study 22940493 — intervention group
Group type: EXPERIMENTAL
Intervention: History of STI (excluding Chlamydia trachomatis)
Number of subjects: 16782
Study 22940493 — intervention group
Group type: EXPERIMENTAL
Intervention: 3+ sexual partners in the past 12 months
Number of subjects: 16782
Study 22941123 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 4
Study 22941123 — intervention group
Group type: COMPARATOR
Intervention: Carotid endarterectomy (CEA)
Number of subjects: 4
Study 22941123 — intervention group
Group type: COMPARATOR
Intervention: Current medical therapy
Number of subjects: 4
Study 22941849 — intervention group
Group type: EXPERIMENTAL
Intervention: Morphine bolus for intraoperative analgesia
Number of subjects: 146
Study 22942205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D deficiency (<50 nmol/L)
Number of subjects: 272
Study 22942205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status
Number of subjects: 272
Study 22942205 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D status and PSI score
Number of subjects: 272
Study 22943030 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy for adherence and depression (CBT-AD), 10 to 12 sessions
Number of subjects: 9
Study 22943074 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab 15 mg/kg, administered as 3 to 5 monthly injections over the RSV season.
Number of subjects: 100
Study 22943924 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide hydrochloride (1 mg BID) in young patients
Number of subjects: 24
Study 22943924 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide hydrochloride (1 mg BID) in elderly patients
Number of subjects: 24
Study 22943924 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxy-anagrelide in young patients
Number of subjects: 24
Study 22943924 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxy-anagrelide in elderly patients
Number of subjects: 24
Study 22943924 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide t1/2 in young patients
Number of subjects: 24
Study 22943924 — intervention group
Group type: EXPERIMENTAL
Intervention: Anagrelide t1/2 in elderly patients
Number of subjects: 24
Study 22943924 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxy-anagrelide t1/2 in young patients
Number of subjects: 24
Study 22943924 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-hydroxy-anagrelide t1/2 in elderly patients
Number of subjects: 24
Study 22943924 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events monitoring
Number of subjects: 24
Study 22944906 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion at doses of 0.05, 0.10, and 0.20 μg/kg per minute
Number of subjects: 170
Study 22944906 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion
Number of subjects: 170
Study 22944906 — intervention group
Group type: EXPERIMENTAL
Intervention: Epinephrine infusion combined with exercise testing
Number of subjects: 170
Study 22944906 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted genetic testing of abnormal patients
Number of subjects: 170
Study 22945767 — intervention group
Group type: EXPERIMENTAL
Intervention: Biodegradable polymer-based sirolimus-eluting stents
Number of subjects: 440
Study 22945767 — intervention group
Group type: COMPARATOR
Intervention: Prolonged clopidogrel therapy (>6 months)
Number of subjects: 440
Study 22946484 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic gallstones
Number of subjects: 2034
Study 22946484 — intervention group
Group type: COMPARATOR
Intervention: Cholecystectomy (1983)
Number of subjects: 2034
Study 22946484 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgically treated SGS (1992-1994)
Number of subjects: 2034
Study 22946484 — intervention group
Group type: COMPARATOR
Intervention: AC (surgically treated vs non-surgically treated)
Number of subjects: 2034